^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SurVaxM (SVN53-67/M57-KLH peptide vaccine)

    i
    Other names: SVN53-67/M57-KLH peptide vaccine, survivin-targeted peptide vaccine, survivin peptide mimic vaccine
    Company:
    Fosun Pharma, MimiVax
    Drug class:
    Survivin inhibitor
    Related drugs:
    3d
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    23d
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    1m
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Mar 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    3ms
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Suspended, Roswell Park Cancer Institute | Not yet recruiting --> Suspended
    Trial suspension
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    6ms
    Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM. (PubMed, Cancer Immunol Immunother)
    A five-gene expression signature and a B cell specific signature predicted survival within the SurVaxM-treated cohort, however, these signatures were not associated with improved outcomes in a similarly treated population obtained from The Cancer Genome Atlas (TCGA) that did not receive immunotherapeutic intervention. Although prospective validation is ongoing, the findings in this discovery cohort specify molecular features of GBM associated with better overall survival and potential responsiveness to immunotherapy with SurVaxM.
    Retrospective data • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine)
    7ms
    Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=19, Completed, Roswell Park Cancer Institute | Recruiting --> Completed | N=14 --> 19 | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Feb 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim) • octreotide acetate
    7ms
    A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, Pediatric Brain Tumor Consortium | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine)
    7ms
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Roswell Park Cancer Institute | N=132 --> 60
    Enrollment change
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    8ms
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Jun 2025 --> Sep 2025
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    10ms
    Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme. (PubMed, Cells)
    SurVaxM, a multiple peptide, survivin-specific vaccine, may assist in tumor cell destruction by eliciting the production of cytotoxic T-cells specific to survivin-expression glioblastoma tumors. Although phase I and II clinical trials suggest relatively safe adverse effects and potential efficacy, additional research is necessary to evaluate further how this vaccine may compare to standard treatment.
    Review • Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    IDH wild-type
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine)
    1year
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2024 --> Jun 2025
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    1year
    A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov)
    P1, N=35, Recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2028 --> Feb 2030 | Trial primary completion date: Aug 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine)